Phase II study of the effect of methyl-CCNU (NSC-95441) on bronchogenic carcinoma.
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy* / Q000276:immunology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D001389:Azirines; D009607:Nitrosourea Compounds; D001761:Bleomycin